Home' Australian Pharmacist : Australian Pharmacist September 2012 Contents Australian Pharmacist September 2012 I ©Pharmaceutical Society of Australia Ltd. 751
Azilect® (rasagiline) is PBS-listed for
Azilect 1mg -- a potent, irreversible
monoamine oxidase type B (MAO-B)
inhibitor -- is indicated for the
symptomatic treatment of idiopathic
Parkinson's disease, as monotherapy
(without concomitant levodopa/
decarboxylase inhibitor therapy) or as
adjunct therapy (with concomitant
As of 1 August 2012, Azilect is PBS-listed on authority (STREAMLINED), for
the treatment of Parkinson's disease.1 Azilect 1mg offers a simple once-daily
dose with no titration, and is well tolerated.2-5 Azilect 1mg is available in 30
tablet packs. For more information refer to the Azilect Approved Product
Information which is available by calling Lundbeck on 1300 721 277.
1. Pharmaceutical Benefits Schedule (PBS). Available at: www.pbs.gov.au.
2. Azilect Approved Product Information.
3. Parkinson Study Group. Arch Neurol 2002; 59: 1937-1943.
4. Parkinson Study Group. Arch Neurol 2005; 62: 241-248.
5. Rascol O et al. Lancet 2005; 365: 947-954.
patient need.' Following a request by the
Paediatric Medicines Advisory Group
(PMAG) to the Pharmaceutical Bene ts
Advisory Committee (PBAC), the PBAC
recommended listing Zinnat Suspension
on the PBS on the basis of a clinical
need in the paediatric population and
acceptable cost e ectiveness.1 The PMAG
indicated that bacterial acute otitis media
was a speci c area of concern and noted
the increased risk of a serum sickness-like
illness in paediatric patients treated with
cefaclor for this condition.2
The suspension form of Zinnat had not
been previously available in Australia.
Zinnat Suspension is indicated for the
treatment of mild to moderately severe
tonsillitis, pharyngitis and acute bacterial
otitis media in paediatric patients
three months to 12 years of age. It is
contraindicated in patients with known
hypersensitivity to cephalosporin
antibiotics or who have experienced a
major allergy to penicillin. Rare cases
of severe hypersensitivity reactions,
including serum sickness-like reaction,
have been reported with cefuroxime
axetil.3 The Therapeutic Guidelines for
Antibiotics lists the use of cefuroxime for
treatment of otitis media in patients who
are hypersensitive to penicillin.4
1. Australian Government, Department of Health and Ageing,
Pharmaceutical Benefits Scheme, Mar 2009 PBAC Outcomes --
Positive Recommendations. Accessed 3 Jun 2012 at: www.pbs.
2. Cefaclor Approved Product Information.
3. Zinnat Suspension Approved Product Information, refer to
www.gsk.com.au/zinnat for the latest version.
4. Antibiotic Expert Group. Therapeutic Guidelines: Antibiotic. V.
14, Melbourne, Therapeutic Guidelines, 2010.
The PBS listing for Prolia® (denosumab)
was extended from 1 August.1 Prolia is
now listed as the sole anti-resorptive
• established postmenopausal
osteoporosis in a woman with fracture
due to minimal trauma; and
• osteoporosis in women aged 70 years
of age and older with a Bone Mineral
Density (BMD) T-score of -2.5 or less.1
It was rst PBS listed in December 2010
as the sole anti-resorptive agent for
women with established postmenopausal
osteoporosis with a fracture due to
minimal trauma; and osteoporotic
women aged 70 years or older with a
BMD T-score of -3.0 or less. Denosumab
is the rst treatment for postmenopausal
osteoporosis that speci cally targets
RANK Ligand, an essential regulator
of osteoclast formation, function
1. Australian Government Department of Health and Ageing,
Pharmaceutical Benefits Scheme, at: www.pbs.gov.au/
2. Lewiecki EM. Women's Health 2009;5(1):15--22.
Canesten Fungal Nail
Bayer has launched Canesten Fungal Nail
Treatment Set -- a new pharmacy only
product for treating fungal nail infection
(FNI) which treats the condition in six to
seven weeks. Research shows six weeks
is the average medication adherence
length within this category.1 To make
diagnosis and treatment of fungal nail
infection simple and easy, an online test
and treatment support program are now
available at: www.canesten.com.au. A
new free app for android and iPhone will
also be available this month. According
to Bayer, after using Canesten Fungal
Nail Treatment Set as directed, patients
will notice visible improvements to their
nail within days. The product works in
two stages; phase 1 helps remove the
infected part of the nail in the rst two
or three weeks, and phase 2 treats the
nail bed in four weeks. Canesten Fungal
Nail Treatment Set works by softening
the infected nail so the infection can be
removed, leaving the healthy part of the
nail in place.
Links Archive Australian Pharmacist October 2012 Australian Pharmacist August 2012 Navigation Previous Page Next Page